BR112021022216A2 - Ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxílico para uso em pacientes com câncer de mama metastático ou avançado - Google Patents

Ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxílico para uso em pacientes com câncer de mama metastático ou avançado

Info

Publication number
BR112021022216A2
BR112021022216A2 BR112021022216A BR112021022216A BR112021022216A2 BR 112021022216 A2 BR112021022216 A2 BR 112021022216A2 BR 112021022216 A BR112021022216 A BR 112021022216A BR 112021022216 A BR112021022216 A BR 112021022216A BR 112021022216 A2 BR112021022216 A2 BR 112021022216A2
Authority
BR
Brazil
Prior art keywords
acid
annulene
oxyphenyl
fluoropropyl
pyrrolidin
Prior art date
Application number
BR112021022216A
Other languages
English (en)
Portuguese (pt)
Inventor
Alice Gosselin
Gautier Paux
Marina Celanovic
Patrick Cohen
Sandrine Anneheim-Herbelin
Sylvaine Cartot-Cotton
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR112021022216A2 publication Critical patent/BR112021022216A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112021022216A 2019-05-09 2020-05-07 Ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxílico para uso em pacientes com câncer de mama metastático ou avançado BR112021022216A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19305593 2019-05-09
EP19305679 2019-05-28
US201962945311P 2019-12-09 2019-12-09
PCT/EP2020/062743 WO2020225375A1 (en) 2019-05-09 2020-05-07 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid for use in metastatic or advanced breast cancer patients

Publications (1)

Publication Number Publication Date
BR112021022216A2 true BR112021022216A2 (pt) 2021-12-28

Family

ID=70681807

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022216A BR112021022216A2 (pt) 2019-05-09 2020-05-07 Ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxílico para uso em pacientes com câncer de mama metastático ou avançado

Country Status (13)

Country Link
US (2) US20200352905A1 (https=)
EP (1) EP3965758A1 (https=)
JP (1) JP2022531898A (https=)
KR (1) KR20220006553A (https=)
CN (1) CN114173776A (https=)
AU (1) AU2020268762A1 (https=)
BR (1) BR112021022216A2 (https=)
CA (1) CA3146346A1 (https=)
IL (1) IL287805A (https=)
MX (1) MX2021013711A (https=)
SG (1) SG11202111979SA (https=)
TW (1) TW202110434A (https=)
WO (1) WO2020225375A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021003440A2 (pt) 2018-09-07 2021-05-18 Sanofi sais de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil) pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxilato de metila e seu processo de preparação
EP4037768B1 (en) 2019-10-01 2023-10-11 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
AU2020399168A1 (en) 2019-12-09 2022-07-28 Sanofi Crystalline form of a 7H-benzo[7]annulene-2-carboxylic acid derivative
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
TW202233572A (zh) 2020-10-19 2022-09-01 法商賽諾菲公司 新穎之經取代的6,7-二氫-5h-苯並[7]輪烯衍生物，其製備方法及其治療用途
WO2022084280A1 (en) 2020-10-19 2022-04-28 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
WO2022106711A1 (en) * 2020-11-23 2022-05-27 Sanofi Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
CN117042771A (zh) * 2021-03-09 2023-11-10 伊莱利利公司 使用serd给药方案的组合治疗癌症的方法
TWI837605B (zh) * 2021-03-09 2024-04-01 美商美國禮來大藥廠 使用serd組合給藥方案治療癌症之方法
TW202400136A (zh) * 2022-03-13 2024-01-01 法商賽諾菲公司 以安森司群(amcenestrant)治療乳癌
TW202543650A (zh) 2024-03-08 2025-11-16 美商海爾達醫療運營公司 異雙官能化合物及其在治療疾病中之用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19833786A1 (de) * 1998-07-18 2000-01-20 Schering Ag Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
EP3089747A1 (en) * 2013-12-06 2016-11-09 F. Hoffmann-La Roche AG Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
KR20250152679A (ko) * 2015-04-29 2025-10-23 래디어스 파마슈티컬스, 인코포레이티드 암을 치료하는 방법
LT3386500T (lt) * 2015-12-09 2022-12-27 The Board Of Trustees Of The University Of Illinois Selektyvūs estrogenų receptorių slopintojai benzotiofeno pagrindu
EA034994B1 (ru) 2016-02-15 2020-04-15 Санофи 6,7-дигидро-5h-бензо[7]аннуленовые производные в качестве модуляторов эстрогеновых рецепторов
EP3434272A1 (en) * 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid

Also Published As

Publication number Publication date
WO2020225375A1 (en) 2020-11-12
MX2021013711A (es) 2021-12-10
CN114173776A (zh) 2022-03-11
SG11202111979SA (en) 2021-11-29
US20200352905A1 (en) 2020-11-12
CA3146346A1 (en) 2020-11-12
JP2022531898A (ja) 2022-07-12
AU2020268762A1 (en) 2021-12-02
KR20220006553A (ko) 2022-01-17
TW202110434A (zh) 2021-03-16
US20240091194A1 (en) 2024-03-21
IL287805A (en) 2022-01-01
EP3965758A1 (en) 2022-03-16

Similar Documents

Publication Publication Date Title
BR112021022216A2 (pt) Ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxílico para uso em pacientes com câncer de mama metastático ou avançado
PH12020500091A1 (en) Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer
MXPA05012155A (es) Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades.
WO2009067397A3 (en) Treatment for solid tumors
IL244727A0 (en) Methods and preparations using immunomodulatory compounds for the treatment and management of cancer and other diseases
TW200500355A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
EP4327877A3 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2007009649A (es) Derivados de meleimida, composiciones farmaceuticas y metodos para el tratamiento del cancer.
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
UA93673C2 (ru) Фармацевтическая композиция, которая содержит омега-карбоксиарилзамещенную дифенилмочевину, для лечения paka
MX2009004908A (es) Compuestos quimicos.
BR112023006531A2 (pt) Inibidores heterocílicos de egfr e/ou her2, para uso no tratamento de câncer
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
EP4364801A3 (en) Optimised dosage of diaminophenothiazines in populations
MX2023006020A (es) Combinacion que comprende abemaciclib y acido 6-(2,4-diclorofenil)-5-[4-[(3s)- 1-(3-fluoropropil)pirrolidin-3-il ]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilico.
WO2020033838A3 (en) Treatment of egfr-mutant cancer
TNSN07294A1 (en) Treatment of metastasized tumors
MX2021015447A (es) Métodos de tratamiento del cáncer dirigidos a tumores fríos.
MA42301B1 (fr) Sel cristallin de fumarate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl)azétidin-1-yl]-méthanone
EA035519B9 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
IL185410A0 (en) Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione in the treatment of parkinson's disease
EP4585269A3 (en) Methods for cancer therapy
BR112015012497A2 (pt) combinações farmacêuticas
EA202090558A1 (ru) Схемы лечения
WO2020232191A8 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2826 DE 06/03/2025.